Nirmatrelvir–Ritonavir (Paxlovid) in Adults with Moderate Renal Impairment
Guideline recommendations endorse nirmatrelvir–ritonavir as the preferred oral antiviral for non‑hospitalized adults with mild‑to‑moderate COVID‑19 who are at risk for progression and can start therapy within five days of symptom onset [1]. Use is recommended when estimated glomerular filtration rate (eGFR) is ≥30 mL/min/1.73 m²; a reduced‑dose regimen is required for eGFR 30–<60 mL/min/1.73 m² [2].
Indications
- Ambulatory adults with laboratory‑confirmed SARS‑CoV‑2 infection.
- Symptom onset ≤5 days before initiation.
- Presence of risk factors for severe disease (e.g., age ≥65 years, comorbidities).
- eGFR ≥30 mL/min/1.73 m² (moderate renal impairment qualifies) [1].
Dosing Adjustments for Moderate Renal Impairment (eGFR 30–<60 mL/min/1.73 m²)
- Reduced‑dose pack: 150 mg nirmatrelvir plus 100 mg ritonavir, taken orally twice daily for 5 days [2].
- No loading dose is required; the reduced dose is administered from day 1 through day 5 [3].
Pharmacokinetic Considerations
- Nirmatrelvir is primarily eliminated by renal excretion; reduced clearance in severe renal dysfunction can lead to drug accumulation [4].
- The reduced‑dose regimen mitigates accumulation while maintaining antiviral exposure in the moderate impairment range [2].
Major Drug‑Interaction Risks
- Ritonavir is a potent CYP3A inhibitor; concomitant use with strong CYP3A substrates can increase their plasma concentrations to potentially toxic levels [4].
- Co‑administration with strong CYP3A inducers can markedly reduce nirmatrelvir exposure and compromise efficacy [4].
- Drugs with narrow therapeutic windows that depend on CYP3A metabolism (e.g., certain anti‑arrhythmics, immunosuppressants, anticoagulants) require dose adjustment, temporary discontinuation, or avoidance during Paxlovid therapy [4].
Practical Management of Interactions
- Review patient medication list for CYP3A substrates, inducers, and inhibitors before prescribing.
- Adjust or hold interacting medications when feasible; monitor levels of drugs with narrow therapeutic indices if continuation is necessary.
- Consult a drug‑interaction database or specialist when uncertainty exists.
Monitoring and Follow‑Up
- Verify baseline renal function to confirm eligibility.
- Counsel patients to complete the full 5‑day course.
- Re‑assess renal function and any interacting medications at the end of therapy.